SEC Form SC 13G/A filed by Rocket Pharmaceuticals Inc. (Amendment)

$RCKT
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $RCKT alert in real time by email
SC 13G/A 1 tv01838-rocketpharmaceutical.htm SCHEDULE 13G/A rocketpharmaceuticalsinc

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G

Under the Securities Exchange Act of 1934
(Amendment No.: 2)*

Name of issuer:  Rocket Pharmaceuticals Inc

Title of Class of Securities:  Common Stock

CUSIP Number:  77313F106

Date of Event Which Requires Filing of this Statement: December 29, 2023

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on the following page(s))

 

 

13G

CUSIP No.:  77313F106

1.  NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

The Vanguard Group - 23-1945930

2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

A. 

B.  X

3.  SEC USE ONLY

4.  CITIZENSHIP OF PLACE OF ORGANIZATION

Pennsylvania

(For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

5.  SOLE VOTING POWER

0

6.  SHARED VOTING POWER

108,058

7.  SOLE DISPOSITIVE POWER

5,264,014

8.  SHARED DISPOSITIVE POWER

183,551

9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,447,565

10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

N/A

11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

6.04%

12.  TYPE OF REPORTING PERSON

IA

 

 

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G
Under the Securities Act of 1934

Item 1(a) - Name of Issuer:

Rocket Pharmaceuticals Inc

Item 1(b) - Address of Issuer's Principal Executive Offices:

9 Cedarbrook Drive
Cranbury, NJ 08512

Item 2(a) - Name of Person Filing:

The Vanguard Group - 23-1945930

Item 2(b) – Address of Principal Business Office or, if none, residence:

100 Vanguard Blvd.
Malvern, PA 19355

Item 2(c) – Citizenship:

Pennsylvania

Item 2(d) - Title of Class of Securities:

Common Stock

Item 2(e) - CUSIP Number

77313F106

Item 3 - Type of Filing:

This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

Item 4 - Ownership:

  (a) Amount Beneficially Owned:

  (b) Percent of Class:

 

 

(c)  Number of shares as to which such person has:

(i)  sole power to vote or direct to vote:  

(ii)  shared power to vote or direct to vote:  

(iii)  sole power to dispose of or to direct the disposition of:  

(iv)  shared power to dispose or to direct the disposition of:  

Comments:

The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

Item 5 - Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

No one other person's interest in the securities reported herein is more than 5%.

Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

Not applicable

Item 8 - Identification and Classification of Members of Group:

Not applicable

Item 9 - Notice of Dissolution of Group:

Not applicable

Item 10 - Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date:  February 13, 2024

By /s/ Ashley Grim
Name: Ashley Grim
Title:  Head of Global Fund Administration

Get the next $RCKT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RCKT

DatePrice TargetRatingAnalyst
3/12/2025$50.00Outperform
BMO Capital Markets
12/30/2024$32.00Outperform
Wedbush
12/18/2024$29.00Buy
Jefferies
10/16/2024Sector Outperform
Scotiabank
4/2/2024$39.00Neutral
Goldman
10/24/2023$65.00Overweight
Cantor Fitzgerald
2/1/2023$45.00Overweight
Morgan Stanley
11/8/2022$53.00Buy
Canaccord Genuity
More analyst ratings

$RCKT
Press Releases

Fastest customizable press release news feed in the world

See more
  • Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

    Dosing ongoing in the Phase 2 pivotal study of RP-A501 for Danon disease; Program update expected in the first half of 2025 New England Journal of Medicine publication of Phase 1 study of RP-A501 to treat patients with Danon disease Long-term data from the Phase 1 trial of RP-A501 for Danon disease presented at AHA on safety and meaningful efficacy Enrollment completed in low dose cohort of Phase 1 study of RP-A601 for PKP2-ACM; Initial data expected in the first half of 2025 Regulatory reviews ongoing for KRESLADI (severe LAD-I) and RP-L102 (Fanconi Anemia) Cash, cash equivalents and investments of approximately $372.3M; expected operational runway into the third quarter of 2026

    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, in San Francisco, California. Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present on Monday, January 13, at 3:45 p.m. PT and host investor meetings throughout the conference. A webcast of the presentation will be available here and will be posted on the Investors section of the Company's website. About Rocket Pharmaceuticals, Inc. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is a

    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced today the pricing of an upsized underwritten public offering of 13,200,000 shares of its common stock at a public offering price of $12.50 per share. The gross proceeds to Rocket from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $165 million. All shares in the offering are to be sold by Rocket. In addition, Rocket has granted the underwriters a 30-day option to purchase up to an additional 1,980,000 shares of its common stock

    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RCKT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$RCKT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$RCKT
SEC Filings

See more

$RCKT
Leadership Updates

Live Leadership Updates

See more
  • Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

    Enrollment completed in September and dosing ongoing in the Phase 2 pivotal study of RP-A501 for Danon disease Updated Phase 1 data from RP-A501 for Danon disease anticipated at American Heart Association's 2024 Late-Breaking Scientific Sessions Enrollment completed in low dose cohort of Phase 1 study of RP-A601 for PKP2-ACM; Preliminary data expected in the first half of 2025 Rolling BLA submission initiated for RP-L102 for Fanconi Anemia Progress on FDA-approval of KRESLADI for severe LAD-I; Approval anticipated in 2025 Appointed Mikael Dolsten, M.D., Ph.D., to Board of Directors Cash, cash equivalents and investments of approximately $235.7M; expected operational runway into 2026

    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of Mikael Dolsten, M.D., Ph.D., as an independent director to its Board of Directors. Dr. Dolsten is an accomplished industry executive with extensive global pharmaceutical management experience. "As an industry-leading pharmaceutical executive, I am very pleased to welcome Mikael to our Board of Directors," said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma. "His research and development experience will help advance our leading scientific capabilities and

    $PFE
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team

    Aaron Ondrey joins as Chief Financial Officer bringing seasoned leadership experience in financial management, strategic planning, commercial finance, and capital allocation Additional key appointments within existing corporate leadership team expand capabilities and expertise spanning early discovery through commercialization Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of Aaron Ondrey, as Chief Financial Officer, and the further evolution of its corporate leadership team through key appointments with existin

    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RCKT
Financials

Live finance-specific insights

See more
  • Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

    — Reported positive safety data at ASGCT from pediatric cohort of Phase 1 Danon Disease study that demonstrated RP-A501 was well-tolerated; efficacy update across pediatric as well as adult cohorts on track for late Q3 2022— — Announced top-line data at ASGCT from pivotal Phase 2 trial for severe LAD-I that showed RP-L201 was well-tolerated with 100% overall survival at one year; regulatory filings anticipated in first half of 2023 — — Primary endpoint met for Fanconi Anemia pivotal Phase 2 trial, FDA dialogue initiated for BLA planning; continued data readouts for Fanconi Anemia and Pyruvate Kinase Deficiency programs expected in Q4 2022 — — Achieved Current Good Manufacturing Practice

    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Progress

    — Continued to advance clinical gene therapy programs for the treatment of Danon Disease, Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I) and Pyruvate Kinase Deficiency (PKD) — — Updates on all four programs to be presented at the 2022 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) this month; trials on track for 2022 data readouts — — Appointed internationally recognized cardiovascular physician-scientist and biopharmaceutical executive Fady Malik, M.D., Ph.D., to Board of Directors – — Named experienced commercial leader Carlos Martin to Chief Commercial Officer and proven biotech executive Jessie Yeung to Vice President of Investor Relations and C

    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease

    —Results demonstrate sustained benefit across clinical, functional and biomarker endpoints in all four patients with long-term follow up— — NYHA class improvement (from II to I) in all three patients (two low-dose, one high-dose) with closely monitored immunosuppressive regimen— —Decreased cardiac wall thickness with improved or stabilized ejection fraction on echocardiogram in all three patients with closely monitored immunosuppressive regimen— — Sustained improvement or stabilization in BNP and 6-minute walk test across four patients— —Sustained cardiac LAMP2B expression greater than 50% by immunohistochemistry and improved cardiac tissue architecture in all three patients with clos

    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RCKT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more